Canaccord raises target for Natera stock from USD 375 to USD 500

Published on 10/21/2026 at 10:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 752.75 million, up 37.70 percent. Natera stock costs EUR 363.60 on October 21, 2026, at USD 58.5 billion.

Analyst momentum meets execution

Canaccord Genuity lifted its Natera target from USD 375.00 to USD 500.00 on October 19, 2026.
Second-quarter 2026 revenue reached USD 752.75 million, while gross margin was 64.00 percent.
Natera held USD 1.09 billion in cash as of June 30, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera, Inc. (US6323071042) drew a higher analyst valuation after MarketBeat reported on October 19, 2026, that Canaccord Genuity raised its Natera target from USD 375.00 to USD 500.00 while maintaining a Buy rating. The move puts execution, rather than demand alone, at the center of the valuation debate.

Targets move higher

The latest target change followed a strong second quarter. MarketBeat reported that Natera generated USD 752.75 million in revenue in the second quarter of 2026, up 37.70 percent from the prior-year quarter. Adjusted earnings per share showed a loss of USD 0.47, better than the USD 0.49 consensus loss.

The sequence of analyst actions shows how quickly expectations have reset. On October 13, 2026, TD Cowen raised its target from USD 340.00 to USD 480.00; on October 14, 2026, JPMorgan raised its target from USD 360.00 to USD 460.00; and on October 19, 2026, Canaccord moved from USD 375.00 to USD 500.00, according to MarketBeat.

What justifies the valuation?

Yahoo Finance reported that gross margin reached 64.50 percent in the second quarter of 2026, compared with 63.40 percent a year earlier. Total tests processed rose 22.40 percent to about 1.04 million, while oncology tests increased 57.20 percent to about 296,700.

The counterweight is profitability. Natera posted a net loss attributable to common shareholders of USD 66.97 million in the second quarter of 2026, while cash and cash equivalents stood at USD 1.09 billion on June 30, 2026. The company also faces the task of converting expanding test volumes into durable operating earnings.

Three dates frame the story

On October 13, 2026, TD Cowen set a USD 480.00 target after USD 340.00. On October 14, 2026, JPMorgan set a USD 460.00 target after USD 360.00. On October 19, 2026, Canaccord set a USD 500.00 target after USD 375.00, according to MarketBeat.

Stock trades after the target reset

Natera's U.S. listing is on NASDAQ under ticker NTRA. Its shares also carry a demanding market valuation: the market capitalization was USD 58.5 billion as of October 20, 2026, while the 52-week range was USD 181.00 to USD 437.41. The next test is whether clinical adoption and reimbursement can support the expectations embedded in the new targets.

Natera was trading at EUR 363.60 at Lang & Schwarz on October 21, 2026, at 10:35 a.m. CEST. The company combines molecular testing, bioinformatics and artificial intelligence across women's health, oncology and organ health.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.